Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...

Dr. Mariano Barbacid, a pioneering Spanish cancer scientist, alongside his team have eliminated aggressive pancreatic tumours ...

Pancreatic cancer is notorious for its late diagnosis and poor prognosis. This is largely due to the pancreas being a deep-seated organ, making early detection difficult. Common symptoms such as: ...

PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the ...

HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

The KRAS gene is responsible for producing a protein also called KRAS that’s involved in regulating the entrance of signaling molecules into the nucleus of a cell. Many of the nuclear signaling ...

Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...